SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Nordenskjöld Bo 1940 )
 

Sökning: WFRF:(Nordenskjöld Bo 1940 ) > Amplification of HS...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003550naa a2200421 4500
001oai:DiVA.org:liu-24842
003SwePub
008091007s2003 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:1950057
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-248422 URI
0247 a https://doi.org/10.1038/sj.onc.12060782 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:19500572 URI
040 a (SwePub)liud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Gunnarsson, Cecilia,d 1970-u Linköpings universitet,Onkologi,Hälsouniversitetet4 aut0 (Swepub:liu)cecgu53
2451 0a Amplification of HSD17B1 and ERBB2 in primary breast cancer
264 c 2003-01-14
264 1b Springer Science and Business Media LLC,c 2003
338 a print2 rdacarrier
520 a Estrogens play a crucial role in the development of breast cancer. Estradiol can be produced in the breast tissue in situ, and one of the enzymes involved in this process is 17β-hydroxysteriod dehydrogenase (17β-HSD) type 1 that catalyzes the interconversion of estrone (E1) to the biologically more potent estradiol (E2). The gene coding for 17β-HSD type 1 (HSD17B1) is located at 17q12-21, close to the more studied ERBB2 and BRCA1. The aim of this study was to investigate if HSD17B1 shows an altered gene copy number in breast cancer. We used real-time PCR and examined 221 postmenopausal breast tumors for amplification of HSD17B1 and ERBB2. In all, 32 tumors (14.5%) showed amplification of HSD17B1 and 21% were amplified for ERBB2. Amplification of the two genes was correlated (P = 0.00078) and in 14 tumors (44%) with amplification of HSD17B1, ERBB2 was co amplified. The patients with amplification in at least one of the genes had a significantly worse outcome than patients without (P = 0.0059). For estrogen receptor (ER)-positive patients who received adjuvant tamoxifen, amplification of HSD17B1 was related to decreased breast cancer survival (P = 0.017), whereas amplification of ERRB2 was not. Amplification of HSD17B1 might be an indicator of adverse prognosis among ER-positive patients, and possibly a mechanism for decreased benefit from tamoxifen treatment.
653 a MEDICINE
653 a MEDICIN
7001 a Ahnström, Marie,d 1976-u Linköpings universitet,Onkologi,Hälsouniversitetet4 aut0 (Swepub:liu)marah62
7001 a Kirschner, Kristinau Linköpings universitet,Kirurgi,Hälsouniversitetet4 aut
7001 a Olsson, Birgit,d 1946-u Department of Oncology, Huddinge University Hospital, Stockholm, Sweden4 aut0 (Swepub:liu)birol93
7001 a Nordenskjöld, Bo,d 1940-u Linköpings universitet,Onkologi,Hälsouniversitetet4 aut0 (Swepub:liu)bono64
7001 a Rutqvist, Lars Eriku Department of Oncology, Huddinge University Hospital, Stockholm, Sweden4 aut
7001 a Skoog, Lambertu Karolinska Institutet4 aut
7001 a Stål, Olle,d 1952-u Linköpings universitet,Onkologi,Hälsouniversitetet4 aut0 (Swepub:liu)ollst87
7102 a Linköpings universitetb Onkologi4 org
7730 t Oncogened : Springer Science and Business Media LLCg 22:1, s. 34-40q 22:1<34-40x 0950-9232x 1476-5594
8564 u https://www.nature.com/articles/1206078.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-24842
8564 8u https://doi.org/10.1038/sj.onc.1206078
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1950057

Hitta via bibliotek

  • Oncogene (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy